Susquehanna International Group, LLP Atara Biotherapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $35,910 - $65,268	12,600 Added 118.87%	23,200 $76,000
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $30,210 - $92,538	10,600 New	10,600 $40,000
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $421,968 - $561,798	35,400 Added 80.82%	79,200 $1.03 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $30,120 - $59,720	4,000 Added 10.05%	43,800 $638,000
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $21,053 - $65,786	3,700 Added 10.25%	39,800 $339,000
Q4 2019 Feb 14, 2020	SELL	$10.89 - $16.79 $136,125 - $209,875	-12,500 Reduced 25.72%	36,100 $595,000
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $319,998 - $530,404	26,600 Added 120.91%	48,600 $686,000
Q2 2019 Aug 14, 2019	SELL	$19.05 - $41.04 $1.72 Million - $3.71 Million	-90,500 Reduced 80.44%	22,000 $442,000
Q1 2019 May 15, 2019	SELL	$28.4 - $41.74 $315,240 - $463,314	-11,100 Reduced 8.98%	112,500 $4.47 Million
Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $2.6 Million - $3.61 Million	84,100 Added 212.91%	123,600 $4.29 Million
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $3.16 Million - $3.92 Million	-90,200 Reduced 69.55%	39,500 $1.63 Million
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $7.28 Million - $10.7 Million	-207,100 Reduced 61.49%	129,700 $4.77 Million
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $5.33 Million - $14.3 Million	296,000 Added 725.49%	336,800 $13.1 Million
Q4 2017 Feb 14, 2018	BUY	$13.2 - $18.1 $178,200 - $244,350	13,500 Added 49.45%	40,800 $738,000
Q3 2017 Nov 20, 2017	BUY	$13.25 - $17.05 $361,725 - $465,465	27,300	27,300 $452,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.47B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account